All In Biotech

Free tool

FAERS Monitor: Parlodel

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017962 or its brand name (Parlodel, Bromocriptine Mesylate). Reports on generic versions are filed under their own applications.

Reports

522

Serious

444

85% of reports

Hospitalization

207

Death reported

28

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea34
  • drug ineffective31
  • headache30
  • pyrexia29
  • vomiting28
  • drug exposure during pregnancy25
  • neuroleptic malignant syndrome24
  • fatigue21
  • dizziness20
  • tremor19
  • blood creatine phosphokinase increased18
  • malaise17
  • drug interaction16
  • dyspnoea16
  • off label use16

Reports by year received

View as table
YearReports
200432
200530
200634
200733
200837
200915
201018
201162
201255
20138
20149
201510
201619
201720
20188
201914
20204
202112
202216
202324
202441
202513
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,637 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neuroleptic malignant syndromeSignal2481.755.21,831
drug exposure during pregnancySignal2529.620.2664
blood creatine phosphokinase increasedSignal1825.216.0395
tremorSignal194.63.051
drug interactionSignal164.12.534
pyrexiaSignal293.42.447
vomitingSignal282.41.722
headache301.91.413
nausea341.71.310
dizziness201.61.14
malaise171.61.03
dyspnoea161.10.70
fatigue211.10.70
drug ineffective310.90.70
off label use160.70.51

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.